Type 2 Diabetes Mellitus
Conditions
Keywords
Type 2 Diabetes Mellitus, Duodenal Mucosal Resurfacing, Intestinal Barrier Function, Gut Microbiome
Brief summary
The aim of this study is to demonstrate the effects of duodenal mucosal resurfacing (DMR) on intestinal barrier function and gut microbiota when treating uncontrolled type 2 diabetes. Subjects who underwent DMR and those who did not were enrolled, and potential differences were identified by analyzing urine and fecal samples through microbiotic analysis and High Performance Liquid Chromatography (HPLC), combined with changes in clinical data.
Detailed description
This study aims to enroll 100 patients diagnosed with type 2 diabetes who have suboptimal control with one or more oral antidiabetic drugs. Of these, 50 will receive DMR treatment at the Metabolic Weight Loss Center of the China-Japan Friendship Hospital and will be followed up, while the other 50, who have not received DMR treatment, will be matched by age and gender for comparison. Each patient or their legal guardian will sign an informed consent form to participate in the study. Researchers will be granted access to the patients' medical records and will collect their medical history and treatment data. Researchers will also collect urine and fecal samples for microbiome analysis，metagenomics-based studies and HPLC, analyzing the changes in intestinal barrier function and gut microbiota before and after DMR treatment, and between DMR-treated and non-DMR-treated patients.
Interventions
PROCEDUREDMR Procedure
Endoscopic procedure
Sponsors
China-Japan Friendship Hospital
Wang Siqi
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
BASIC_SCIENCE
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
25 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
\- 1.25-65 years of age. 2.Diagnosed with type 2 diabetes. 3.Glycated Hemoglobin (HbA1c) of 7.5 - 10.0% (59-86 mmol/mol). 4.Body Mass Index (BMI) ≥ 24 and ≤ 40 kg/m2. 5.Currently taking one or more oral glucose lowering medications, with no changes in dose or medication in the previous 12 Weeks prior to study entry. 6.Able to comply with study requirements and understand and sign the informed consent.
Exclusion criteria
1. Clinical diagnosis of type 1 diabetes. 2. Current use of Glucagon-like peptide-1 (GLP-1) analogues. 3. Hypoglycemia unawareness or a history of severe hypoglycemia. 4. Clinical diagnosis of autoimmune disease. 5. Previous gastrointestinal surgery that could affect the ability to treat the duodenum. 6. Use of anticoagulation therapy (such as warfarin) which cannot be discontinued for 7 days before and 14 days after the procedure. 7. Clinical diagnosis of anemia. 8. Not potential candidates for surgery or general anesthesia. 9. Participating in another ongoing clinical trial of an investigational drug or device. 10. Any other mental or physical condition which, in the opinion of the Investigator, makes the subject a poor candidate for clinical trial participation.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Microbiome Analysis | one week and one month post-treatment | Characterization of of gut microbiome using next generation sequencing technology |
| High Performance Liquid Chromatography | one week and one month post-treatment | Intestinal barrier function using HPLC technology |
Contacts
Primary Contactsiqi Wang, Doctor
Backup ContactHua Meng, Doctor
Outcome results
None listed